Molecular Biosystems of San Diego has extended Mallinckrodt Medical'srights to its FS069 ultrasound contrast agent to Europe, Russia,Africa, and India. In exchange for the new rights, Mallinckrodtof St. Louis will pay MBI fees of up to $12.9 million,
Molecular Biosystems of San Diego has extended Mallinckrodt Medical's
rights to its FS069 ultrasound contrast agent to Europe, Russia,
Africa, and India. In exchange for the new rights, Mallinckrodt
of St. Louis will pay MBI fees of up to $12.9 million, plus 40%
of product sales for royalties and manufacturing. The companies
filed a premarket approval application for U.S. marketing of FS069,
a second-generation contrast agent, earlier this year. They plan
to file for European approval in early 1997.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Stroke MRI Study Assesses Impact of Motion Artifacts Upon AI and Radiologist Lesion Detection
July 16th 2025Noting a 7.4 percent incidence of motion artifacts on brain MRI scans for suspected stroke patients, the authors of a new study found that motion artifacts can reduce radiologist and AI accuracy for detecting hemorrhagic lesions.